fromSilicon Canals
5 days agoMosanna Therapeutics raises 70.1M to disrupt sleep apnea treatment with nasal spray - Silicon Canals
This is a great achievement by the Mosanna team! As investors since the seed round and in this Series A, we are excited to see MOS118 advance into the clinical stage. The simple mode of application via a nasal spray has the potential to drastically improve the life of patients suffering from sleep apnea.
Startup companies